Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
106 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Atrial Fibrillation - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Atrial Fibrillation - Pipeline Review, H2 2014', provides an overview of the Atrial Fibrillation's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Atrial Fibrillation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Atrial Fibrillation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Atrial Fibrillation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Atrial Fibrillation Overview 9 Therapeutics Development 10 Pipeline Products for Atrial Fibrillation - Overview 10 Pipeline Products for Atrial Fibrillation - Comparative Analysis 11 Atrial Fibrillation - Therapeutics under Development by Companies 12 Atrial Fibrillation - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Atrial Fibrillation - Products under Development by Companies 17 Atrial Fibrillation - Companies Involved in Therapeutics Development 18 Bristol-Myers Squibb Company 18 AstraZeneca PLC 19 Isis Pharmaceuticals, Inc. 20 Gilead Sciences, Inc. 21 Daiichi Sankyo Company, Limited 22 Nissan Chemical Industries, Ltd. 23 Laboratoires Pierre Fabre SA 24 Cardiome Pharma Corp 25 Xention Limited 26 HUYA Bioscience International, LLC 27 Milestone Pharmaceuticals, Inc. 28 Otsuka Holdings Co., Ltd. 29 Serodus ASA 30 Nyken BV 31 Armetheon, Inc. 32 Atrial Fibrillation - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Combination Products 34 Assessment by Target 35 Assessment by Mechanism of Action 38 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 edoxaban tosylate - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 tecarfarin - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 vernakalant hydrochloride - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 bucindolol hydrochloride - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 vernakalant hydrochloride - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 ranolazine ER - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 XEN-D0103 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 HBI-3000 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 ISIS-CRPRx - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 (ranolazine + dronedarone) - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 vanoxerine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 F-373280 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 BMS-919373 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 XEN-D0101 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 OPC-108459 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 budiodarone - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Small Molecule to Inhibit IKACh for Atrial Fibrillation - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 MSP-2017 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 NYK-1112 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 SER-102 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 XEN-R0702 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 GsMTx-4 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 NIP-151 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Drug For Atrial Fibrillation - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Atrial Fibrillation - Recent Pipeline Updates 83 Atrial Fibrillation - Dormant Projects 95 Atrial Fibrillation - Discontinued Products 96 Atrial Fibrillation - Product Development Milestones 97 Featured News & Press Releases 97 Aug 19, 2014: First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting 97 Aug 06, 2014: Cardiome Submits Brinavess Dossier To French Authorities To Support Market Access 97 Aug 05, 2014: Cardiome Submits Brinavess Reimbursement Dossier To Belgian Authorities 98 Jul 17, 2014: Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis (apixaban) in Patients with NVAF Undergoing Cardioversion 98 Jul 07, 2014: Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo for Phase 3 Studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban 99 Jun 20, 2014: Boehringer Ingelheim Initiates RE-CIRCUIT Trial, Evaluating Pradaxa (dabigatran etexilate mesylate) in NVAF Patients Undergoing Ablation 100 Jun 20, 2014: New Pradaxa clinical study to explore practical management of patients with atrial fibrillation undergoing ablation 101 May 10, 2014: Gilead Announces Results from Phase 2 Study Showing Reduction in Atrial Fibrillation Burden with the Investigational Combination of Ranolazine and Low-Dose Dronedarone 102 Apr 14, 2014: Portola Pharmaceuticals Announces Publication of Phase 3 APEX Study Design and Rationale in American Heart Journal 103 Mar 31, 2014: Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion 104 Appendix 105 Methodology 105 Coverage 105 Secondary Research 105 Primary Research 105 Expert Panel Validation 105 Contact Us 106 Disclaimer 106
List of Tables Number of Products under Development for Atrial Fibrillation, H2 2014 10 Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H2 2014 18 Atrial Fibrillation - Pipeline by AstraZeneca PLC, H2 2014 19 Atrial Fibrillation - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 20 Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H2 2014 21 Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 22 Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H2 2014 23 Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H2 2014 24 Atrial Fibrillation - Pipeline by Cardiome Pharma Corp, H2 2014 25 Atrial Fibrillation - Pipeline by Xention Limited, H2 2014 26 Atrial Fibrillation - Pipeline by HUYA Bioscience International, LLC, H2 2014 27 Atrial Fibrillation - Pipeline by Milestone Pharmaceuticals, Inc., H2 2014 28 Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 29 Atrial Fibrillation - Pipeline by Serodus ASA, H2 2014 30 Atrial Fibrillation - Pipeline by Nyken BV, H2 2014 31 Atrial Fibrillation - Pipeline by Armetheon, Inc., H2 2014 32 Assessment by Monotherapy Products, H2 2014 33 Assessment by Combination Products, H2 2014 34 Number of Products by Stage and Target, H2 2014 37 Number of Products by Stage and Mechanism of Action, H2 2014 40 Number of Products by Stage and Route of Administration, H2 2014 42 Number of Products by Stage and Molecule Type, H2 2014 44 Atrial Fibrillation Therapeutics - Recent Pipeline Updates, H2 2014 83 Atrial Fibrillation - Dormant Projects, H2 2014 95 Atrial Fibrillation - Discontinued Products, H2 2014 96
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
